TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Dr. Ronald De Crom
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management

An independent study demonstrated that retreatment with MicroPulse® transscleral laser technology can safely reduce intraocular pressure in glaucoma patients, with IOP reductions ranging from 25% to 35% across different patient groups.

Insights
IRIX   positive

The study validates the company's MicroPulse® technology as an effective, repeatable, and safe treatment for glaucoma, potentially expanding market opportunities and clinical credibility